Comparison · NCT05710224-sae
V181 vs Butantan - DV: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. V181 vs Butantan - DV: serious adverse events. Trial comparisons, record NCT05710224-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05710224-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0176 | 0.0101 | 0.0306 | wilson | |
| Risk in group 2 | 0.0133 | 0.007 | 0.025 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00437 | -0.00959 | 0.0188 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.564 | 3.13 | log | |
| Odds ratio, group 1 over group 2 | 1.34 | 0.559 | 3.19 | log | |
| Number needed to harm, for one more participant with a serious adverse event on V181 than on Butantan - DV | 229 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | V181 | Participants received a single 0.5 mL SC injection of V181. | 12 | 680 | EG000 |
| Group 2 | Butantan - DV | Participants received a single 0.5 mL SC injection of Butantan - DV. | 9 | 678 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to ~20 months
Source ClinicalTrials.gov
Trial
- Title
- Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
- NCT number
- NCT05710224
- Phases
- PHASE2
- Conditions
- Dengue
- Interventions
- V181, Butantan - DV
- Lead sponsor
- Butantan Institute
- Results first posted
- 2025-11-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05710224?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05710224-sae